Currently out of the existing stock ratings of Maxwell Skor, 7 are a BUY (77.78%), 2 are a HOLD (22.22%).

Maxwell Skor

Work Performance Price Targets & Ratings Chart

Analyst Maxwell Skor, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 58.33% that have a potential upside of 33.51% achieved within 120 days.

Maxwell Skor’s has documented 18 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ASND, Ascendis Pharma AS at 22-Jul-2026.

Wall Street Analyst Maxwell Skor

Analyst best performing recommendations are on INSM (INSMED).
The best stock recommendation documented was for INSM (INSMED) at 8/20/2025. The price target of $144 was fulfilled within 13 days with a profit of $14.55 (11.24%) receiving and performance score of 8.65.

Average potential price target upside

ASND Ascendis Pharma AS CYTK Cytokinetics FOLD Amicus Therapeutics INSM Insmed PHVS Pharvaris BV SANA Sana Biotechnology

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 06-Jan-2025

$329

$80.5 (32.39%)

$345

Buy Since 15-Apr-2025

$290

$41.5 (16.70%)

$280

Buy Since 03-Sep-2024

$341

$92.5 (37.22%)

$325

Buy Since 02-Jul-2025

$275

$26.5 (10.66%)

$250

Buy Since 20-Apr-2020

$355

$94.25 (36.15%)

$243

Show more analysts

Please expand the browser size to see the chart

Which stock is Maxwell Skor is most bullish on?

Potential upside of $26.5 has been obtained for ASND (ASCENDIS PHARMA AS)

What Year was the first public recommendation made by Maxwell Skor?

On 2025

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?